Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FerGene
The biotech could have the best-in-class KRAS inhibitor, but the departure of two senior executives has given investors the jitters as Mirati heads towards its first regulatory filing.
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.
After more than three decades being associated with Novo Nordisk, Lars Rebien Sørensen has signed up to be chairman of Ferring, telling Scrip that the privately owned Swiss group's philosophy chimes with his own.
Sanofi Pasteur head David Loew has been at the heart of the company's bids to develop vaccines for COVID-19 but has decided to accept a different challenge instead and take the helm at Ipsen.
- Gene Therapy, Cell Therapy